Related Experiment Video
Updated: Mar 19, 2026
05:26
A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
Published on: September 16, 2022
4.8K
Summary
The largest liquid biopsy study shows blood-based circulating tumor DNA (ctDNA) analysis mirrors tissue biopsy genetic changes. This blood test may help monitor resistance to targeted cancer therapies.
Area of Science:
- Oncology
- Genomics
- Molecular Diagnostics
Background:
- Conventional tissue biopsies are invasive and may not capture tumor heterogeneity.
- Liquid biopsies offer a less invasive alternative for cancer genetic profiling.
Discussion:
- This study, the largest of its kind, validates liquid biopsy's ability to detect genetic alterations found in tissue biopsies.
- Circulating tumor DNA (ctDNA) analysis in plasma provides a comprehensive genetic landscape comparable to tissue.
- The findings support ctDNA as a reliable biomarker for cancer management.
Key Insights:
- Genetic profiles from liquid biopsies (ctDNA) closely align with those from traditional tissue biopsies.
- Liquid biopsies represent a significant advancement in non-invasive cancer diagnostics.
- ctDNA sequencing effectively captures tumor genetic changes.
Outlook:
- Sequencing ctDNA in plasma is a promising tool for monitoring treatment response and the emergence of drug resistance.
- This approach could personalize cancer treatment strategies and improve patient outcomes.
- Future research should focus on integrating ctDNA analysis into routine clinical practice for targeted therapy monitoring.
